Sydney, Feb 23, 2026, 18:24 AEDT — Market closed.
Pro Medicus shares fell 8.9% on Monday to A$115.30, deepening a selloff that has pushed the radiology software maker back toward its recent lows. (TradingView)
The stock finished the day near the bottom of its A$115.30–A$127.58 range and not far above its 52-week low of A$113.67, after peaking at A$336.00 over the past year. (Investing)
With the cash session now shut, the question for Tuesday is whether the fall draws bargain-hunters or simply flushes more holders who chased the stock during last year’s surge. There was no fresh company announcement on Monday that clearly explained the late-day slide.
The move added to a choppy stretch: the stock fell 2.1% on Feb. 20, rose 5.0% on Feb. 19 and dropped 2.4% on Feb. 18, data showed. (Investing)
The selling has trailed Pro Medicus’ half-year report earlier this month. In its interim financial report for the six months ended Dec. 31, the company booked revenue of A$128.9 million and profit of A$171.2 million, with A$149.0 million of that coming from fair value movements on other financial assets; it also disclosed A$10.14 million of on-market buybacks at an average price of A$245.21 and declared a 32-cent interim dividend payable on March 20. (Company Announcements)
On the earnings call, Chief Executive Sam Hupert leaned into the industry buzz around automated image analysis, saying, “We believe we are ideally positioned to leverage AI. It is a plus rather than a threat,” and flagged that “forward revenue for 5 years, based on minimums, has broken through the AUD 1 billion mark.” He said the U.S. remained the main market, with roughly 90% of revenue coming from it. (Investing)
Investors have been watching whether contract wins and implementations can keep compounding fast enough to justify the premium valuation the stock carried through last year. Pro Medicus’ software is used to view and manage medical images, and its growth pitch rests on winning large U.S. health systems and rolling them out quickly.
But the trade cuts both ways. Any hint of slower signings, delayed go-lives or tougher pricing could keep pressure on a stock that has become a momentum name — and one that can gap on small shifts in expectations.
The next near-term marker is the Feb. 26 ex-dividend date for the 32-cent interim payout (fully franked, meaning it carries Australian tax credits). (Yahoo)
